Excessive production of eicosanoids is characteristic of many inflammatory diseases. In this study we show that ceramide, which is an early messenger of inflammatory cytokine action, exerts a dual effect on the cytosolic phospholipase A 2 (cPLA 2 ), the rate-limiting enzyme in arachidonic acid release and subsequent eicosanoid formation. Stimulation of renal mesangial cells with exogenous short-chain ceramide analogs for 30 and 60 min leads to a concentrationdependent increase in arachidonic acid release that is not blocked by specific inhibitors of mitogen-activated protein kinase pathways. This suggests that these established upstream activators of cPLA 2 are not involved in ceramide-induced arachidonic acid release. By use of photoactivatable ceramide analogs, D-and L-[ 125 I]3-trifluoromethyl-3-(m-iodophenyl)diazirineceramides (TID-ceramides), we observed a direct interaction of ceramide with cPLA 2 . This interaction was independent of the absolute configuration as D-and L-TID-ceramide were equally effective in binding to cPLA 2 . Moreover, recombinant CaLB domain of cPLA 2 as well as a mutant deficient in the connecting 'hinge' domain of cPLA 2 , efficiently bound D-and L-TIDceramides, whereas the catalytic domain did not interact with TID-ceramides. In vitro binding assays reveal that stearoyl-arachidonyl-phosphatidylcholine (SAPC)-liposomes containing increasing mol% of ceramide lead to an increased association of recombinant cPLA 2 to the liposomes. Furthermore, measurement of cPLA 2 activity in vitro shows that the presence of SAPC-liposomes resulted in only weak cPLA 2 activity. However, the activity dramatically increases by addition of ceramide to the liposomes. Furthermore, liposomes containing SAPC and sphingomyelin resulted in no better substrate than SAPC liposomes, unless bacterial sphingomyelinase was added to generate ceramide, which then causes a marked increase in cPLA 2 activity. These results demonstrate that ceramide can interact directly with cPLA 2 via the CaLB domain and thereby serves as a membrane-docking device that facilitates cPLA 2 action in inflammatory diseases.
he release of arachidonic acid from membrane phospholipids is a key step in the biosynthesis of eicosanoids, of which many have important signaling functions and are involved in cross-communication between cells. In the kidney, eicosanoids play crucial roles in many physiological and pathophysiological processes, such as regulation of intrarenal vascular tone, distribution of renal blood flow, and modulation of salt and water transport; they also contribute to glomerular injury (1) . Arachidonic acid release is mediated essentially by phospholipases A 2 (2, 3) . In recent years it has become evident that phospholipases A 2 are a heterogeneous family of enzymes that may be grouped into two main classes based on their molecular mass and cellular distribution (4) . The class of low-molecular-weight secreted phospholipases A 2 and the high-molecular-weight cytosolic phospholipases A 2 (cPLA 2 ) 1 , which is further subdivided into a Ca 2+ -dependent and a Ca 2+ -independent group.
It has been described that cPLA 2 selectively liberates arachidonic acid and is responsible for eicosanoid synthesis observed after exposure of cells to Ca 2+ -mobilizing hormones (5) . The cPLA 2 is translocated by low concentrations of Ca 2+ to membranes in a process using a Ca 2+ -dependent phospholipid-binding (CaLB) domain in the N-terminal part of the enzyme and is subsequently activated by phosphorylation (5, 6) . Phosphorylation recognition sites for protein kinase C (PKC), protein kinase A, mitogen-activated protein kinase (MAPK), and protein tyrosine kinases have been identified (6) .
Ceramide is a novel lipid second messenger that has attracted increasing interest during the past few years due to its potential role in growth inhibition and promotion of cell death and differentiation (for review: (7) (8) (9) (10) ). Ceramide can be generated either by the action of sphingomyelinases, which hydrolyse sphingomyelin to form phosphocholine and ceramide, or by de-novo synthesis from sphinganine by the action of a ceramide synthase. Classical activators of sphingomyelin turnover and ceramide generation include stressful stimuli such as heat shock; UV irradiation; the proinflammatory cytokines interleukin-1 and tumor necrosis factor-a; cell differentiation inducers such as vitamin D 3 and retinoic acid; and other cell-damaging substances like chemotherapeutics and nitric oxide (9, 11, 12) .
That proinflammatory cytokines, which are potent inducers of phospholipases A 2 and prostaglandin formation, also trigger ceramide formation in many cell types prompted us to investigate the mechanism of ceramide action on phospholipases A 2 . It is worth noting that cPLA 2 has a CaLB domain in its N-terminal part, which makes it an attractive candidate for direct ceramide binding and thus might be instrumental in solving the long-standing question of a putative ceramide-binding motif (12) .
In this study, we demonstrate that ceramide can interact directly with the CaLB domain of cPLA 2 , which thereby drags the enzyme to the membrane. This function is critical as ceramide leads to an activation of cPLA 2 in vivo in mesangial cells, but it does not directly activate cPLA 2 in a cell-free system. Obviously ceramide rather serves as a membrane-docking molecule, bringing the enzyme to its substrate and arranging it to allow efficient arachidonic acid release.
MATERIALS AND METHODS

T
Cell culture
Rat renal mesangial cells were cultivated and characterized as previously described (13, 14) . In a second step, single cells were cloned by limited dilution on 96-microwell plates. Clone MZ B 1 , with apparent mesangial cell morphology, was used for further processing. The cells were grown in RPMI 1640 supplemented with 10% (v/v) fetal-calf serum, penicillin (100 units/ml), streptomycin (100 mg/ml), and bovine insulin (0.66 unit/ml). For the experiments, passages 7-20 of the cells were used. 3 H]arachidonic acid. The cells were then stimulated with vehicle or the agonists as indicated. Thereafter, the medium was removed and centrifuged. Cells were dissolved in 0.5 M NaOH, and radioactivity was counted in the supernatants and cell extracts in a scintillation counter. The percentage of [ 3 H]arachidonic acid released from total incorporated radioactivity was calculated.
Determination of arachidonic acid release
Construction and expression of recombinant baculovirus carrying wildtype cPLA 2 , the catalytic domain or the CaLB domain of cPLA 2 The recombinant transfer plasmid (pBacPAK8) containing cPLA 2 cDNA (kindly provided by Dr. Jeff Browning, Biogen Inc., Mass., U.S.A.), the CaLB domain (amino acids 1-131), or the catalytic domain (amino acids 132-749) was cotransfected with Bsu361-digested BacPAK6 viral DNA into IPBL-Spodoptera fugiperda 21 cells (Sf21 cells) by using the CLONTECH BacPAK Baculovirus Expression System, and recombinant virus was plaque purified according to the manufacturer's recommendation (15). The Sf21 cell line was propagated as a monolayer in Graces supplemented insect medium (supplemented with yeastolate and lactalbumin hydrolysate) containing 10% (v/v) fetal calf serum and 1% (w/v) antibiotic/antimycotic solution at 27°C. For production of CaLB domain, catalytic domain or cPLA 2 protein, 35-mm-dishes with 5 x 10 5 cells per dish were infected with 100 ml plaquepick for 1h. The infected cells were covered with 2 ml medium and grown for 4 days at 27°C. The medium was removed, and 1 ml of phosphate-buffered saline (PBS) was added to each dish. The cells were scarped into PBS and thereafter centrifuged for 1 min at 1000 x g. Cells were then resuspended in PBS and repelleted. The supernatant was then removed, and the cell pellet was used for binding assays.
TID labeling studies
A combination of 1 mg partially purified cPLA 2 
In vitro assay of cPLA 2 activity
In vitro cPLA 2 activity was assayed with sonicated liposomes containing 5 mM of [ 14 C]stearoylarachidonyl-PC (SAPC; 60000dpm), including C16-ceramide or other phospholipids at the indicated mol%. The assay mixture in a total volume of 200 ml contained 5 ng of recombinant cPLA 2 in 200 mM Tris, pH 8.5, 1 mM CaCl 2 . Incubations were carried out for 10 min at 37°C and stopped by addition of 2.5 ml of Dole reagent (isopropanol/heptane/2 N sulfuric acid, 40: 10: 1, vol/vol), 1.5 ml of heptane, and 1 ml of water. After vortexing, 1 ml of the upper phase was separated over a silicic acid column (200 ml of volume; 100-200 mesh Bio-sil A) and washed with 1 ml of diethylether. The eluate containing [
14 C]arachidonic acid was counted in a b-counter.
Binding assay
The association of cPLA 2 with large unilamellar vesicles (LUVs) containing differing concentrations of ceramide was determined as described by Mosior et al. (16) . In brief, LUVs were prepared by extrusion in 170 mM sucrose, 20 mM 1,4-piperazinediethane sulfonic acid (PIPES), and pH 6.8 and were diluted in 5 volumes of binding buffer (100 mM KCl, 20 mM PIPES, pH 6.8). After centrifugation at 200,000 x g for 20 min, the pellet containing the LUVs was resuspended in binding buffer containing 0.1 mg/ml BSA. Thereafter, purified cPLA 2 was added (0.375 mg/ml) and incubated for 15 min at room temperature in the absence or presence of 1 mM CaCl 2 . The lipid/enzyme suspension was recentrifuged for 20 min at 200,000 x g. The supernatant, containing unbound cPLA 2 , and the pellet fraction, containing LUV-bound cPLA 2 , were dissolved in SDS-Laemmli buffer, subjected to SDS-PAGE (7.5% acrylamide gel), and transferred to nitrocellulose; Western blot analysis was performed by using a specific polyclonal cPLA 2 antibody (17) at a dilution of 1:1000.
Statistical analysis
Statistical analysis was performed by one-way analysis of variance. For multiple comparisons with the same control group, the limit of significance was divided by the number of comparisons according to Bonferroni. 14 C]SAPC; specific activity: 56 mCi/mmol) were purchased from Amersham International, Amersham, Bucks., U.K.; anti-rabbit alkaline phosphatase-linked IgG and silicic acid Bio-sil A were from Bio-Rad Labs., München, Germany; sphingomyelin, PD98059 and RO 31 8220 were from Calbiochem-Novabiochem, Schwalbach, Germany; stearoyl-arachidonyl-phosphatidylcholine (SAPC) and dioleoylglycerol were from Avanti Polar, Alabaster, Ala., U.S.A.; C2-, C6-and C16-ceramides were from Biotrend Chemikalien GmbH, Köln, Germany; all cell-culture nutrients were from Life Technology, Karlsruhe, Germany; the
Chemicals
]-TID-ceramide) was synthesized as described (18) and provided kindly by Professor Josef Brunner, ETH Zürich, Switzerland. Polyclonal antiserum against cPLA 2 , human recombinant cPLA 2 , and mutant 1 of cPLA 2 were kindly provided by Dr. Ruth Kramer, Lilly Research Laboratories, Indianapolis, Ind.
RESULTS
Ceramide induces arachidonic acid release from mesangial cells
Stimulation of [
3 H]arachidonic acid-labeled mesangial cells with short-chain (C6) or long-chain (C16) ceramides reveals a dose-dependent increase in [ 3 H]arachidonic acid release after 60 min of stimulation (Fig. 1) .It is interesting that the long-chain C16-ceramide was found to be more potent than the short-chain C6-ceramide to stimulate arachidonic acid release ( Fig. 1) . This finding agrees with previous data, showing that long-chain C16-ceramide is also more potent than the C2-and the C6-ceramide in activating the c-Raf and the classical MAPK activity in rat mesangial cells (19) . These data provide evidence that exogenous ceramide activates cPLA 2 activity in mesangial cells, which subsequently causes release of arachidonic acid from prelabeled phospholipids. In contrast, addition of phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidic acid (PA) up to concentrations of 12 mM did not result in a significant increase in arachidonic acid release (Fig.  1B) . Phosphatidylinositol bisphosphate (PIP 2 ) was the only phospholipid that caused a significant release of arachidonic acid already at a concentration of 8 mM (Fig. 1B) . However, all phospholipids resulted in a nonspecific arachidonic acid release at concentrations of 25 mM or more (data not shown).
Preincubation of mesangial cells with either an inhibitor of the classical MAPK cascade, PD 98059 (20) (up to 20 mM), or an inhibitor of PKC, Ro 31-8220 (21) (at 1 mM), revealed no significant reduction of ceramide-induced arachidonic acid release (data not shown), suggesting that the classical MAPK cascade and the conventional and novel PKCs are not involved in the ceramide-triggered response.
Direct binding of TID-ceramide to cPLA 2
To evaluate whether cPLA 2 is activated as a consequence of ceramide stimulation of c-Raf and the classical MAPK cascade (19) , which is well-established to trigger cPLA 2 activity (22), and/or whether cPLA 2 is a direct target of ceramide due to its N-terminal CaLB domain, we used a photoaffinity labeling analog of ceramide, [ 125 I]3-trifluoromethyl-3-(m-iodophenyl)diazirineceramide (TID-ceramide) of high [ 125 I]-iodine-specific radioactivity (> 2000 Ci/mmol ) (18) and incubated recombinant cPLA 2 with this compound in a cell-free system for 5 min followed by photolysis at 364 nm. As seen in Figure 2A , there is a strong labeling of cPLA 2 by TIDceramide. It is interesting that there was no difference in labeling between the D-and L-erythro isomers of TID-ceramide, which suggests that that the absolute configuration is not critical for binding to cPLA 2 .
It is obvious that the calcium-dependent lipid binding (CaLB) domain of cPLA 2 is an attractive candidate for ceramide binding (12) , and we therefore generated mutants of cPLA 2 that lack the CaLB domain. Using the baculovirus expression system, we produced (i) the catalytic domain of cPLA 2 , containing amino acid residues 132-749, which is devoid of the CaLB domain (cat); (ii) as a control, the isolated CaLB domain containing the amino acids 1-131; and (iii) a mutant of cPLA 2 lacking the hinge region that links the CaLB domain to the catalytic domain (containing residues 1-147/459-749; Mut1).
As shown in Figure 2A , the catalytic domain of cPLA 2 , which runs as an approximately 78-kDa polypeptide on SDS-PAGE, as verified by a Western blot analysis using an antibody against cPLA2 (Fig. 2B) , did not bind [
125 I]-TID-ceramide; whereas the mutant lacking the hinge region in cPLA 2 (Mut1) could still bind to TID-ceramide ( Fig. 2A) . Moreover, the insect cell lysates containing recombinant CaLB domain showed a strong [
125 I]-labeling at 14.4 kDa, the predicted size of the CaLB fragment (Fig. 3A) . Again, no preference in binding was detected for the Dand L-isomers of [
125 I]-TID ceramide. To prove that the 14.4-kDa polypeptide expressed in insect cells and labeled with [ 125 I]-TID ceramide is identical to the CaLB domain, Western blot analysis of insect cell lysates was performed by using a polyclonal antibody raised against the recombinant wildtype cPLA 2 (17) . It is interesting that the autoradiogramm of the TID-ceramide binding (Fig. 3A) revealed an additional labeled band at a size of approximately 29 kDa. It is notable that this band was also detected in the Western blot analysis with the specific cPLA 2 -specific antibody (Fig. 3B) in insect cell lysates transfected with either empty baculovirus (lane 3) or CaLB-encoding virus (lane 2). It may be hypothesized that this 29-kDa cPLA 2 -immunoreactive band represents an endogenous baculovirus-cPLA 2, which also can bind ceramide.
Most important is that the TID-ceramide binding to cPLA 2 was completely Ca 2+ -dependent, as in the absence of Ca 2+ ; TID-ceramide binding to cPLA 2 was completely abrogated (Fig. 4, lane 3) , which supports an argument for a specific binding of ceramide. Moreover, another group of PLA 2 was tested for TID-ceramide binding-the low-molecular-weight secreted PLA 2 , the sPLA 2 -which shows no sequence homology to cPLA 2 and also lacks a CaLB domain but still contains the hydrophobic substrate-binding site. However, no binding of TID-ceramide to recombinant group II A sPLA 2 was detected (data not shown).
Binding studies of cPLA 2 to ceramide-containing liposomes
Lipid binding or covalent modification of proteins often serves to translocate proteins preferentially to specific membrane compartments as exemplified by myristoylation of endothelial NO synthase (23, 24) , farnesylation of p21 ras (25) , palmitoylation of the a-subunits of heterotrimeric G proteins and members of the Src family (24, 26) , or diacylglycerol binding to PKC (27, 28). To examine whether ceramide can target cPLA 2 to the membrane and thus bring the enzyme to its substrate, and in this way facilitate cPLA 2 activation, we performed in vitro translocation studies with PC/ceramide liposomes according to the method established by Mosior et al. (16) . As shown in Figure 5 , increasing mol% of ceramide in the PC-liposomes led to an increased translocation of cPLA 2 from the soluble fraction (Fig. 5A) to the membrane-like liposome fraction (Fig. 5B) .
cPLA 2 activity in vitro
In vitro activity assays were performed to determine whether ceramide binding to cPLA 2 is accompanied by an activation of the enzyme. As depicted in Figure 6A , there is only a suboptimal activation of cPLA 2 in the presence of SAPC liposomes alone. However, supplementation of diacylglycerol to the substrate [ 14 C]SAPC at a molar ratio of 2:1 led to a further 6-fold activation of cPLA 2 and thus confirmed previous observations by Leslie and Channon (29) . These authors hypothesized that diacylglycerol may loosen the membrane integrity of the PC-containing liposomes and thereby allow the cPLA 2 to get access to its substrate.
When diacylglycerol was replaced by natural ceramide, an almost equally potent activation of cPLA 2 was observed (Fig. 6A) . Combining SAPC with diacylglycerol and ceramide at a molar ratio of 2:0.5:0.5 revealed no further potentiation of cPLA 2 activation as compared with SAPC/diacylglycerol or SAPC/ceramide, respectively. Moreover, liposomes containing SAPC and sphingomyelin were prepared and tested for cPLA 2 activation in vitro. Under this condition, again a suboptimal activation was achieved comparable with the SAPC liposomes alone. However, when bacterial sphingomyelinase was added to SAPC/sphingomyelin liposomes, a dose-dependent increase in cPLA 2 activity was observed confirming that ceramide, generated by the action of bacterial sphingomyelinase, is sufficient to stimulate cPLA 2 activity. This activation was Ca 2+ -dependent because, in the absence of Ca 2+ , cPLA 2 activity was completely blocked (Fig. 6A) . This effect of ceramide was concentration-dependent as shown in Figure 6B . Already at 0.1 mol% of ceramide, an increase in cPLA 2 activity is detected, which is in line with the observed cPLA 2 binding to liposomes (Figs. 5A, B) .
Next, we compared the effects of various phospholipids on cPLA 2 activity. As shown in Figure  7 , addition of 33 mol% of PS, PI, or PA caused no significant changes in cPLA 2 activity. Only PIP 2 resulted in a marked increase in cPLA 2 activity, confirming observations reported by Mosior et al. (16) . In contrast, 33 mol% of PE even caused a pronounced reduction of cPLA 2 activity.
DISCUSSION
In the present study we identified cPLA 2 as a further direct target of the lipid-signaling molecule ceramide. This study, once more, documents the versatility of the photoactivatable [
125 I]TIDceramide in the search for specific ceramide-binding proteins, which has already previously led to the identification of c-Raf, PKC-a, and -d isoenzymes. In this way, the operationally defined terms of ceramide-activated protein kinase (CAPK) and ceramide-activated protein phosphatase can now be filled step by step with molecularly defined entities.
It is interesting that the ceramide targets identified by this approach so far, have either tandem repeats of cystein-rich motifs, a so-called zinc butterfly (PKC-a, PKC-d, c-Raf) or a CaLB domain (cPLA 2 , PKC-a), or both (PKC-a). From these earlier data it was tempting to speculate that there could be a common ceramide-binding motif. The conserved C1 and C2 domains in the regulatory part of PKC isoenzymes are candidates for lipid-interacting motifs. The C2 part present in the conventional cPKCs contains a CaLB domain that is responsible for interaction with phospholipids. The C1 part present in all PKC isoenzymes contains a so-called zinc butterfly, which is thought to be responsible for binding DAG and phorbol esters (30) . There is a whole list of further CaLB domain-containing proteins, including the phospholipase C-b, -g, and -d isoenzymes, p120 GAP , synaptotagmin, Unc-13, rabphilin-3A, receptor for activated C kinase (RACKS), different PI3K isoform and the cPLA 2 (12) . Whether all proteins containing a CaLB domain will bind ceramide is still unclear because the CaLB domains in the different proteins show differential lipid-binding properties. However, our present results clearly identify the CaLB domain as a ceramide-binding domain within the cPLA 2 .
It has been reported that the CaLB domain of cPLA 2 penetrates into the nonpolar core of the membrane via hydrophobic interactions; whereas the CaLB domain of synaptotagmin only interacts with lipid membranes via electrostatic interactions, which can be abolished by high salt concentrations (31) . The binding of TID-ceramide to the CaLB domain seems to be specific and not due simply to an interaction with a hydrophobic sequence because there is no binding to the catalytic domain of cPLA 2 , which lacks the CaLB domain but still contains another hydrophobic domain, the substrate-binding site. In addition, there is no binding of ceramide to the group II A sPLA 2 (data not shown), which lacks the CaLB domain but still contains the hydrophobic substrate-binding domain.
It is important to note that the ceramide binding to the CaLB domain is Ca 2+-dependent, thus confirming other reports that Ca 2+ ions are a prerequisite for lipid binding to the CaLB domain (29, 31, 32) It is worth noting that in the absence of Ca 2+ , neither a binding of cPLA 2 to TIDceramide nor a translocation of cPLA 2 to ceramide-containing liposomes nor an activation of cPLA 2 in a cell-free system was observed. Thus, there is a close correlation between cPLA 2 binding to ceramide and the increase of enzymatic activity.
With respect to other direct targets of ceramide identified by ceramide-binding studies, suggestions for several ceramide-activated enzymes have been forwarded. These suggestions include the protein kinase C-z isoenzyme (33), the lysosomal protease cathepsin D (34) , and the mitochondrial cytochrom C1 (35) . It is surprising that PKC-z was found to bind ceramide in U937 cells (33) but not in renal mesangial cells (36) , although in the latter case ceramide was reported to bind specifically to PKC-a and -d isoenzymes. This differential behavior of ceramide binding is not understood but may be related to cell-type specific expression of protein partners known to bind to PKC-isoenzymes by protein-protein interaction and thus may shield under certain conditions the putative ceramide-binding motif. This hypothesis is under current investigation in our laboratory.
Another important question concerns the functional consequences of ceramide binding to target proteins. Whereas c-Raf and PKC-a are activated by ceramide binding and deliver signals into the extracellular signal-regulated kinase (ERK) pathway or mediate feedback-regulation of hormone-stimulated phosphoinositide turnover, respectively (19, 36) , ceramide inhibits PKC-d isoenzyme with yet unknown consequences (36) .
In the present study we explored the direct effect of ceramide on cytosolic PLA 2 activation and initiation of an inflammatory reaction. It is well-accepted that proinflammatory cytokines like interleukin-1b and tumor necrosis factor-a, which are potent inducers of arachidonic acid release and prostaglandin synthesis in a variety of cell lines, are also activators of the sphingomyelin cycle, leading to the generation of the lipid second messenger ceramide. From these findings it was quite obvious to assume an involvement of ceramide in arachidonic acid release and PLA 2 activation. Indeed, when [ 3 H]arachidonic acid-labeled renal mesangial cells were stimulated with exogenous ceramide of different chain lengths, we observed a dose-dependent release of [ 3 H]arachidonic acid after 60 min of stimulation. A similar effect of ceramide was also reported for breast cancer epithelial cells (37), P388D1 macrophages (38) , and platelets (39).
Clearly, there is a cross-communication between the sphingomyelin pathway and cPLA 2 activation and arachidonic acid release, which suggests a key role of sphingomyelinases in the onset of eicosanoid-evoked inflammatory reactions. Because sphingomyelinases exist as a family of several subtypes divided into acidic and neutral enzymes, the identification of the relevant subtype, which contributes to the ceramide-mediated cPLA 2 activation, is of considerable interest. Due to subcellular localization, the neutral sphingomyelinases, localized at the plasma membrane or at microsomes, are the more likely candidates than the lysosomal acidic sphingomyelinase.
Because unstimulated mesangial cells express only two forms of PLA 2 , the cytosolic Ca 2+ -dependent PLA 2 (cPLA 2 ) and the cytosolic Ca 2+ -independent iPLA 2 , but no secretory PLA 2 , only the former two enzymes may be responsible for the observed short-term effect of ceramide on arachidonic acid release. However, as there is strong evidence that iPLA 2 is not primarily involved in signaling but rather plays a role in phospholipid remodeling this PLA 2 subtype is unlikely to contribute to ceramide signaling (40) .
Recently, Huang et al. (41, 42) reported that natural ceramide modulates PLA 2 activity in vitro by perturbing the structure of phospholipid bilayers. In their studies they used cobra venom PLA 2 , which belongs to the group IA of sPLA 2 . In contrast, we show here for the first time that the group IV cPLA 2 , but not the group IIA sPLA 2 , is modulated directly by ceramide.
We found it interesting that that liposomes containing SAPC and sphingomyelin did not show an increased activation of cPLA 2 as compared with SAPC liposomes alone. However, the simultaneous addition of bacterial sphingomyelinase, which cleaves sphingomyelin to generate ceramide, led to a significant increase in cPLA 2 activation and SAPC hydrolysis. These data clearly indicate that ceramide generation does facilitate cPLA 2 activation, probably by attracting cPLA 2 to the membrane and thereby providing improved access to its substrate SAPC. This conclusion is stressed by the findings that (i) synthetic TID-ceramide directly binds to cPLA 2 in vitro (Fig. 2) , and (ii) ceramide-containing liposomes cause an increased translocation of cPLA 2 to the liposomes (Fig. 5) .
In intact mesangial cells, ceramide can induce arachidonic acid release within 30-60 min of stimulation. In addition to targeting cPLA 2 to the membrane compartment, this stimulating effect of ceramide on arachidonic acid release may also be mediated indirectly via PKC or the MAPK pathway. These two kinase families can be activated by ceramide (19, 36, 43) , and they have also been shown to phosphorylate and activate the cPLA 2 . The fact that neither PKC inhibitors nor a MEK inhibitor can block ceramide-induced arachidonic acid release (data not shown) suggests that direct modulation of cPLA 2 activity by ceramide is the functionally more relevant event.
A prerequisite for the demonstrated lipid-protein interaction to occur in vivo is that ceramide, generated by the action of a sphingomyelinase, and cPLA 2 are located in the same cell compartment. Concerning the cellular localization of cPLA 2 , several controversial reports have been provided, localizing activated cPLA 2 to the plasma membrane (44) , to the nuclear envelope (45) , or to the endoplasmatic reticulum (45) . In a further study, cPLA 2 has been found in "punctuate structures" within the cell, which, however, have not been further characterized (46) . Concerning ceramide generation, several studies have suggested that ceramide signaling is initiated in so-called caveolae, which are detergent-insoluble membrane domains especially enriched in sphingolipids (48) . In other reports, neutral sphingomyelinase activity was localized in the plasma membrane as well as in microsomes, assuming that ceramide is generated in these compartments (49, 50) . Also, ceramide can be formed in the lysosomes by the action of an acidic sphingomyelinase (51), however, it is very unlikely that lysosomal ceramide contributes to cPLA 2 activation.
In summary, we have provided in this study evidence that cPLA 2 is a novel direct partner for ceramide binding. Ceramide, in turn, causes improved membrane docking of cPLA 2 resulting in enhanced arachidonic acid mobilization and prostaglandin synthesis. Tracing ceramide-binding partners is important in determining the diverse functional roles of this lipid molecule and may finally provide means for novel antiinflammatory therapeutic strategies. 2 was incubated with liposomes containing stearoyl-arachidonyl-PC with the indicated mol% C16-ceramide for 15 min at 23°C. Thereafter, membrane-bound cPLA 2 was separated from unbound soluble cPLA 2 by ultracentrifugation as described. Supernatants containing soluble cPLA 2 and pellets containing membrane-bound cPLA 2 were separated on SDS-PAGE (8% acrylamide gel), transferred to nitrocellulose, and subjected to a Western blot analysis by using a polyclonal antibody against cPLA 2 at a dilution of 1:1000. Bands corresponding to cPLA 2 were evaluated on a densitometer (Biorad). Data are means ± S.D. (n = 2-5). 
